ARMLUPEG
Launchpegfilgrastim-unne
BLASOLUTIONINJECTION
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ARMLUPEG (pegfilgrastim-unne) is colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. First approved in 2025.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARMLUPEG (pegfilgrastim-unne) is a biosimilar granulocyte colony-stimulating factor (G-CSF) indicated for chemotherapy-induced neutropenia and breast cancer support. It works by binding to cell surface receptors on hematopoietic cells to stimulate proliferation, differentiation, and functional activation of neutrophils. This is a BLA-approved biologic administered as a subcutaneous injection.
Growth
As a newly launched biosimilar in a mature supportive care market, this product offers growth potential but faces established competition; team size will scale with market penetration strategy and reimbursement success.
Mechanism of Action
colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining ARMLUPEG offers exposure to biosimilar commercialization and payer negotiation during a critical market transition as NEULASTA faces LOE. This is a launch-stage opportunity with growth potential but limited clinical differentiation, making commercial execution and market access expertise highly valued.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.